GlassScriptPhysician profile
Jose Lutzky
NPI 1235127929
$46,503.73
in general payments reported to CMS, 2019-2025
46 companies · $6,740 in 2025
The $6,740 reported for 2025 was more than what 85% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $24K · 2020: $3,309 · 2021: $1,728 · 2022: $3,743 · 2023: $705 · 2024: $6,518 · 2025: $6,740.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $5,600 · Consulting Fee: $5,506 · Food and Beverage: $2,567 · Travel and Lodging: $190 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $5,600.00 |
| Consulting Fee | $5,506.25 |
| Food and Beverage | $2,566.80 |
| Travel and Lodging | $190.37 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Array Biopharma INC | $12,478.09 | 2019-2025 | Braftovi, Mektovi, Tukysa |
| Genzyme Corporation | $12,074.88 | 2019-2020 | |
| Regeneron Pharmaceuticals, INC. | $5,732.89 | 2023-2025 | Libtayo |
| Immunocore Limited | $3,771.64 | 2023-2025 | Kimmtrak |
| Regeneron Healthcare Solutions, INC. | $3,071.42 | 2019-2024 | Libtayo |
| Iovance Biotherapeutics, INC. | $2,545.05 | 2025 | Amtagvi |
| Eisai INC. | $1,662.88 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $797.27 | 2019-2025 | Opdivo |
| Pfizer INC. | $609.01 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $506.68 | 2019-2025 | Keytruda |
| Janssen Biotech, INC. | $373.27 | 2019-2025 | Darzalex, Tecvayli, Rybrevant |
| Trisalus Life Sciences, INC. | $360.09 | 2022-2023 | Trinav Infusion System |
| Astrazeneca Pharmaceuticals LP | $292.18 | 2019-2025 | Tagrisso, Calquence |
| Novartis Pharmaceuticals Corporation | $256.68 | 2019 | |
| Genentech USA, INC. | $242.54 | 2019 |
Show all 42 companies
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jose Lutzky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.